CRDF vs. NRIX, ELVN, NTLA, BGM, RCUS, VIR, RCKT, COLL, XNCR, and REPL
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), Intellia Therapeutics (NTLA), Qilian International Holding Group (BGM), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT), Collegium Pharmaceutical (COLL), Xencor (XNCR), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs.
Cardiff Oncology (NASDAQ:CRDF) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.
Cardiff Oncology has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.
Nurix Therapeutics received 39 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 77.88% of users gave Nurix Therapeutics an outperform vote while only 64.62% of users gave Cardiff Oncology an outperform vote.
In the previous week, Nurix Therapeutics had 18 more articles in the media than Cardiff Oncology. MarketBeat recorded 19 mentions for Nurix Therapeutics and 1 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.54 beat Nurix Therapeutics' score of 0.97 indicating that Cardiff Oncology is being referred to more favorably in the media.
16.3% of Cardiff Oncology shares are held by institutional investors. 7.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Nurix Therapeutics has a net margin of -354.85% compared to Cardiff Oncology's net margin of -6,238.17%. Nurix Therapeutics' return on equity of -53.65% beat Cardiff Oncology's return on equity.
Cardiff Oncology currently has a consensus price target of $11.67, suggesting a potential upside of 206.61%. Nurix Therapeutics has a consensus price target of $30.88, suggesting a potential upside of 139.86%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, research analysts plainly believe Cardiff Oncology is more favorable than Nurix Therapeutics.
Cardiff Oncology has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Cardiff Oncology and Nurix Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy CRDF Stock Free CRDF Stock Alerts